Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size

Masamitsu Suhara, Yutaka Miura, Horacio Cabral, Daisuke Akagi, Yasutaka Anraku, Akihiro Kishimura, Masaya Sano, Takuya Miyazaki, Noriko Nakamura, Ayako Nishiyama, Kazunori Kataoka, Hiroyuki Koyama, Katsuyuki Hoshina

研究成果: ジャーナルへの寄稿記事

抄録

Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.

元の言語英語
ページ(範囲)394-401
ページ数8
ジャーナルJournal of Controlled Release
286
DOI
出版物ステータス出版済み - 9 28 2018

Fingerprint

Nanomedicine
Peripheral Arterial Disease
Ischemia
Extremities
Arteries
Endovascular Procedures
Arterioles
Micelles
Drug Delivery Systems
Hindlimb
Phagocytes
Therapeutics
Macrophages
Pharmacology

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size. / Suhara, Masamitsu; Miura, Yutaka; Cabral, Horacio; Akagi, Daisuke; Anraku, Yasutaka; Kishimura, Akihiro; Sano, Masaya; Miyazaki, Takuya; Nakamura, Noriko; Nishiyama, Ayako; Kataoka, Kazunori; Koyama, Hiroyuki; Hoshina, Katsuyuki.

:: Journal of Controlled Release, 巻 286, 28.09.2018, p. 394-401.

研究成果: ジャーナルへの寄稿記事

Suhara, M, Miura, Y, Cabral, H, Akagi, D, Anraku, Y, Kishimura, A, Sano, M, Miyazaki, T, Nakamura, N, Nishiyama, A, Kataoka, K, Koyama, H & Hoshina, K 2018, 'Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size', Journal of Controlled Release, 巻. 286, pp. 394-401. https://doi.org/10.1016/j.jconrel.2018.07.049
Suhara, Masamitsu ; Miura, Yutaka ; Cabral, Horacio ; Akagi, Daisuke ; Anraku, Yasutaka ; Kishimura, Akihiro ; Sano, Masaya ; Miyazaki, Takuya ; Nakamura, Noriko ; Nishiyama, Ayako ; Kataoka, Kazunori ; Koyama, Hiroyuki ; Hoshina, Katsuyuki. / Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size. :: Journal of Controlled Release. 2018 ; 巻 286. pp. 394-401.
@article{0c5a9077bb4444b5856b02b52675f3e7,
title = "Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size",
abstract = "Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.",
author = "Masamitsu Suhara and Yutaka Miura and Horacio Cabral and Daisuke Akagi and Yasutaka Anraku and Akihiro Kishimura and Masaya Sano and Takuya Miyazaki and Noriko Nakamura and Ayako Nishiyama and Kazunori Kataoka and Hiroyuki Koyama and Katsuyuki Hoshina",
year = "2018",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2018.07.049",
language = "English",
volume = "286",
pages = "394--401",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size

AU - Suhara, Masamitsu

AU - Miura, Yutaka

AU - Cabral, Horacio

AU - Akagi, Daisuke

AU - Anraku, Yasutaka

AU - Kishimura, Akihiro

AU - Sano, Masaya

AU - Miyazaki, Takuya

AU - Nakamura, Noriko

AU - Nishiyama, Ayako

AU - Kataoka, Kazunori

AU - Koyama, Hiroyuki

AU - Hoshina, Katsuyuki

PY - 2018/9/28

Y1 - 2018/9/28

N2 - Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.

AB - Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.

UR - http://www.scopus.com/inward/record.url?scp=85051258230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051258230&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.07.049

DO - 10.1016/j.jconrel.2018.07.049

M3 - Article

AN - SCOPUS:85051258230

VL - 286

SP - 394

EP - 401

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -